Abstract
Overview
Introduction
Detailed analysis of the Asthma and COPD market. 10 year sales forecast for
all major drugs brands in these indications, taking into account new treatment
trends, clinical trial data, patent expirations and key new product launches
in the 7 major markets.
Scope
- Indication based forecasts for asthma/COPD products and significant
pipeline drugs
- Assessment of country-specific drivers and resistors likely to impact the
market
- Future market outlook for individual products taking into account key
market events, in particular patent expiry and competitor launch dates
- Market overview by geographical area, with value analysis of clinical and
commercial factors underlying product performance
Report Highlights
Asthma/COPD sales in the seven major markets are expected to grow to over $24
billion annually by 2010 and drop slightly thereafter due to patent expiries
of key products. The ICS/LABA class is set to remain the leading class by
value throughout, while the LAMA market will experience the strongest growth,
particularly in COPD.
A once-daily LABA/LAMA product should become the top-selling single brand in
the seven major markets in 2016, depending on which company launches such a
combination product first. However, combined sales of the Advair franchise
(Advair/Seretide and once-daily Beyond Advair) will dominate the asthma/COPD
market over the next ten years.
The phase-out of CFC-containing inhalers in the US after 2008 will have a big
impact on the market for short-acting beta2-agonists (SABAs), increasing this
class' size significantly. The main beneficiary is expected to be IVAX' s (now
Teva) ProAir due to its favourable price compared with other marketed HFA
SABAs.
Reasons to Purchase
- Identify key opportunities and threats that will impact the use and uptake
of new and existing products
- Quantify the future size and scope of the asthma/COPD market and predict
the future performance of key compounds
- Understand and capitalize on clinical unmet needs in the market, either
through lifecycle management of marketed drugs or new product development
| 
View Cart
